NCT07012044View on ClinicalTrials.gov

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Acute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

DRUG

Decitabine

Given PO

DRUG

Decitabine and Cedazuridine

Given PO

BIOLOGICAL

Filgrastim

Given SC or IV

PROCEDURE

Imaging Procedure

Undergo diagnostic imaging

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH